Perspectives on the diagnosis of respiratory infections worldwide


Dublin, 06 Oct 2021 (GLOBE NEWSWIRE) – The report “Respiratory Infections Diagnostics Markets by Technology, Plex, Location, Product and Region with Covid-19 Impact and Forecast / Analysis and Executive Guides and consultants 2021-2025 “has been added to offer.

COVID-19 has opened the market for point-of-care respiratory infection testing. Now the competition for market share is starting in earnest. Great new markets are opening up. In health facilities, clinics, doctors’ offices and elsewhere. And let’s not forget the testing market, not only for COVID, but the rest of the 20 respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors attempt to position themselves in new markets that are not yet fully understood.

New technologies are forever changing the diagnosis of respiratory infections. The reduction in the time to obtain results opens up markets several times larger than the current practice based on microbiology. The diagnosis has already moved to the emergency room. He is now moving to the lab in the doctor’s office. Could the house be next?

The multiplex factor is confusing the market while reducing costs and improving care, but important factors are holding back progress. The widespread nature of respiratory infections (young people can catch 8 colds a year) means that the potential size of the market is huge. Respiratory diseases, already the largest category of infectious diseases, could increase. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this detailed report.

Our research makes you the expert in your organization. Make our research team work for you by ordering all or part of this full report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don’t worry, your order is available as a credit if you want to move on to more information. We have written this report and are ready, by phone or email, to help you use it. As always, support and additional specific data are provided at no additional cost.

Main topics covered:

1 Market guide

2 Market introduction and definition

3 Market overview
3.1 The players in a dynamic market
3.1.1 University research laboratory
3.1.2 Developer of diagnostic tests
3.1.3 Instrument supplier
3.1.4 Distributor and reagent supplier
3.1.5 Independent test laboratory
3.1.6 Public National / regional laboratory
3.1.7 Hospital laboratory
3.1.8 Physician’s Office Laboratories
3.1.9 Supervisory body
3.1.10 Certification body
3.2 Respiratory infections
3.2.1 Higher or lower – Marketing implications
3.2.2 Understanding the role of pneumonia
3.2.3 Bacterial infections Streptococcal infections Acute otitis media Bacterial rhinosinusitis Diphtheria Pneumococcal pneumonia Haemophilus pneumonia Mycoplasma pneumonia (foot pneumonia) Chlamydial pneumonia and psittacosis Healthcare-associated pneumonia Pseudomonas pneumonia Legionnaire’s disease
3.2.4 Tuberculosis – A special case
3.2.5 Viral infections The common cold Influenza Viral pneumonia SARS and MERS Measles (rubella) Rubella (German measles) Chickenpox and shingles
3.2.6 Fungi and other pathogens Histoplasmosis Coccidioidomycosis Blastomycosis Mucormycosis Aspergillosis Pneumocystis pneumonia Cryptococcosis
3.3 Diagnostics – A changing role
3.3.1 Historical practice
3.3.2 Current diagnosis
3.3.3 The multiplex vector
3.3.4 Future diagnoses – The question of when and where
3.3.5 Diagnosis of respiratory infections – The destination
3.3.6 Diagnostics as defensive weapons
3.4 COVID-19
3.4.1 Signs and symptoms
3.4.2 Gearbox
3.4.3 Diagnosis
3.4.4 Prevention
3.4.5 Management
3.4.6 Prognosis
3.5 Pandemic diagnosis
3.5.1 Risk management – Spark and Spread
3.5.2 Dx Technology – Nucleic Acid Based
3.5.3 Dx Technology – Immunoassay and Serology
3.5.4 Time to market and preparation issues
3.5.5 Unrecognized role of the multiplex in pandemic management

4 market trends
4.1 Growth factors
4.1.1 Syndromic multiplexing
4.1.2 TAT
4.1.3 Antimicrobial Resistance Movement
4.1.4 Pandemic mitigation
4.1.5 An aging population at risk
4.2 Factors limiting growth
4.2.1 The cost curve
4.2.2 Regulation and coverage
4.2.3 laissez-faire
4.3 Instrumentation and automation
4.3.1 The retractable multiplexing machine
4.3.2 Bioinformatics Networking and Anonymous Reporting
4.4 Development of diagnostic technology
4.4.1 The key role of result time
4.4.2 Single-cell genomics is a game-changer
4.4.3 Pharmacogenomics confuses diagnosis and treatment
4.4.4 Identification of pathogens – A provisional timetable for the future

5 Diagnosis of respiratory infections Recent developments
5.1 Recent Developments – Importance and How to Use This Section
5.1.1 Significance of these changes
5.1.2 How to use this section
5.2 LGC is developing a “very high speed” COVID workflow
5.3 Cue Health Files for IPOs up to $ 100 million
5.4 QuantuMDx Development Multiplex System, Syndromic Panels
5.5 Bio-Rad Laboratories Obtains CE Mark for RT-PCR Breath Test Kit
5.6 BforCure Preparing multiple panels for the PoC qPCR platform
5.7 Angstrom Bio raises $ 3 million in private funding
5.8 Test them all
5.9 Hologic Banking on MDx acquisitions
5.10 The pandemic pushes portable qPCR devices closer to commercialization
5.11 Talis Biomedical 2020 revenues increase strongly
5.12 Luminex will develop a Covid / Flu / RSV test
5.13 Becton Dickinson charts the transition of COVID diagnoses
5.14 MiRxes Receives Approval for Covid / Flu Multiplex Test
5.15 New silicon-based test for the detection of infectious diseases
5.16 GenMark to meet the demand for respiratory panels
5.17 Tempus announces COVID-19 tests and data initiative
5.18 Abacus Diagnostica Ready Multiplex Breath Test
5.19 Qiagen acquires NeuMoDx Molecular
5.20 Companies move to multiplex testing for SARS-CoV-2 and influenza
5.21 Novacyt obtains CE marking for the coronavirus, influenza and RSV combo panel
5.22 Cepheid Launches 10-Color Technology With New Tuberculosis Control Test
5.23 The BioMérieux Pneumonia panel could improve care
5.24 Mammoth Biosciences Announces CRISPR-Based Diagnosis of C19
5.25 Genetic signatures obtains the CE mark for the C19 molecular test
5.26 Qiagen Respiratory Panel with C19 Receives CE Mark
5.27 Lumos Diagnostics Closes $ 15 Million Series A Funding
5.28 Fusion Genomics to Evaluate the NGS Airway Test
5.29 Development of C19 tests by co-diagnosis
5.30 Rapid Diagnostics completes purchase of Enigma Diagnostics
5.31 An influenza-like epidemic could kill 80 million people worldwide
5.32 Startup developing AI for tuberculosis detection
5.33 The Nipah virus, a global threat
5.34 Novacyt SA: a new respiratory panel ready for the American market
5.35 New Ebola cases in DRC confirmed as FDA OK test
5.36 ResApp obtains CE mark for telephone breath test
5.37 Curetis submits lower respiratory tract infection test for FDA clearance
5.38 New test diagnoses pneumonia and other lower respiratory tract infections
5.39 Ontera obtains contract for Zika genotyping test
5.40 Two new members join the global diagnostics network
5.41 BARDA Financing of Health Security Solutions

6 profiles of key players
6.1 Abacus Diagnostica
6.2 Abbott diagnostics
6.3 Speed ​​up diagnostics
6.4 Ador Diagnosis
6.5 Akonni biosystems
6.6 Alvéo Technologies
6.7 BioCode applied
6.8 Aus diagnostics
6.9 Beckman Coulter Diagnosis
6.10 Becton, Dickinson and company
6.11 Binx Health
6.12 Biocartis
6.13 BioMérieux Diagnostics
6.14 Bio-Rad Laboratories, Inc.
6.15 Bosch Healthcare Solutions GmbH
6.16 Cepheid (now Danaher)
6.17 Co-Diagnosis
6.18 Credo Biomedical Diagnostics
6.19 Benchmarks health
6.20 Curetis SA / Curetis GmbH
6.21 Diagénode Diagnostics
6.22 Diascopic
6.23 Diasorin SpA
6.24 Enzo Life Sciences, Inc
6.25 Eurofins Scientific
6.26 Fluxergy
6.27 Lightning Genetics
6.28 Genomic fusion
6.29 Genetic signatures
6.30 GenMark Dx
6.31 Hiberge Diagnostics
6.32 Hologically
6.33 Immunexpress
6.34 Inflammatix
6.35 Invetech
6.36 Janssen diagnostics
6.37 Karius
6.38 Lexagen
6.39 LightDeck diagnostics
6.40 Luminex Corp
6.41 Lumos diagnostic
6.42 Mammoth Biosciences
6.43 Maxim Biomedical
6.44 Bioscience of meridians
6.45 Mesa Biotech
6.46 Millipore Sigma
6.47 Mindray
6.48 Mobidiag
6.49 Ecological
6.50 Nanomix
6.51 Operon
6.52 Oxford Nanopore Technologies
6.53 Panagen
6.54 Perkin Elmer
6.55 Primer design
6.56 Prominex
6.57 Qiagen GmbH
6.58 Quantumdx
6.59 Quidelle
6.60 Roche Molecular Diagnostics
6.61 Saw diagnosis
6.62 Seegene
6.63 Siemens Healthineers
6.64 Sona Nanotech
6.65 SpeedDx
6.66 T2 Biosystems
6.67 Thermo Fisher Scientific Inc.
6.68 Veramarx
6.69 Veredus Laboratories
6.70 Visby Medical
6.71 XCR diagnostics

7 The Global Respiratory Infections Diagnostics Market
7.1 Global Market by Country
7.2 Global Market by Technology – Overview
7.3 Global Market by Plex – Overview
7.4 Global Market by Location – Overview
7.5 Global Market by Product – Overview

8 Global Respiratory Infections Diagnostics Markets – By Technology

9 Global Respiratory Infections Diagnostics Markets – By Plex

10 Global Respiratory Infections Diagnostics Market – By Location

11 Global Respiratory Infections Diagnostics Market – By Product

12 Appendices

For more information on this report, visit


Leave A Reply

Your email address will not be published.